Orexo's share is listed on NasdaqOMX Stockholm, Sweden (ORX), and is available as American Depository Receipts on OTCQX market in the US (OXROY).
Share price
Name
0.00
0 SEK (0%)
HH:MM CET • 20YY-MM-DD
Annual General Meeting
Our shareholders were invited to attend the 2024 Annual General Meeting on April 26. Find out what decisions were taken and other information ahead of the AGM under the Corporate Governance section - AGM
Annual and Sustainability Report 2023
The Annual and Sustainability Report 2023 was published on March 28, at 8 am CET
ESG sustainability investing
Orexo has established a social financing framework
Presentation of Q4 2023 incl. the Full Year Report
Click the link to watch the presentation on February 8.
Latest CEO Comments
FEBRUARY 8, 2024
"Strong recovery in financial results and FDA initiated the review of OX124"
Read the latest CEO comments from Nikolaj Sørensen
Key financial figures
Group net revenue
639 MSEK
Last Twelve Months, Q123-Q423
Group EBITDA
-32 MSEK
Last Twelve Months, Q123-Q423
US Pharma segment EBIT
283 MSEK
Last Twelve Months, Q123-Q423
Cash position
171 MSEK
Q423
News flow
Press Releases and News
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
Orexo strengthens its sustainability work by establishing a social financing framework
Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds
